Shares of Atossa Therapeutics (ATOS) have done what shares of most companies in the hunt for coronavirus solutions have done in 2020 – …
The world’s focus has zeroed in on healthcare companies. Hardly a surprising turn of events in these pandemic driven times.
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Atossa Genetics …
In a research note issued Thursday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Atossa (ATOS), with a $10 price target, …
Atossa Genetics (NASDAQ:ATOS) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 17% upturn. …
A wave of reverse stock splits appears almost inevitable, as battered stocks try to maintain their stock listing and win over investors who …
Atossa Genetics Inc (NASDAQ:ATOS) investors are upbeat today upon news that this biotech player’s breast health program is getting an expansion. Specifically, the …
Shares of tiny-cap biopharma Atossa Genetics Inc (NASDAQ:ATOS) are falling nearly 25% on Friday, after the company announced 2017 financial results yesterday afternoon. …
Following Phase 1 trial data for Atossa’s oral endoxifen, Maxim’s Jason Kolbert spotlights 208% in return potential for the stock.
Atossa Genetics is among the biotech stock movers in after-hours trading Thursday.